ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

EP: 1.Unmet Needs in Multiple Myeloma Ahead of ASCO 2024

EP: 2.Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024

EP: 3.MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024

EP: 4.Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024

Now Viewing

EP: 5.ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

EP: 6.Future Directions in the Management of Multiple Myeloma

Video content above is prompted by the following questions:

1. Discuss the data presented at ASCO 2024 on the DREAMM-8 study (NCT04484623) of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). (Abstract)
   1. What was the objective of this study?
   2. How was this study designed/what methodology was used?
   3. What results were presented?
      1. N=155
      2. Median follow-up: 21.78 months
      3. PFS
      4. ORR
      5. Median duration of response
      6. OS
      7. Safety
2. Please provide your key takeaways from this study.How might these findings impact the management of patients with RRMM?
3. Belantamab mafodotin was previously withdrawn from the US market for RRMM following results from the phase 3 DREAMM-3 trial (NCT04162210) which did not meet its primary endpoint of progression-free survival (PFS). How do the results of the DREAMM-8 trial shed light on potential advantages of BPd in patients with RRMM?